A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

BACKGROUND: Veliparib is a potent poly(ADP-ribose) polymerase inhibitor. This phase 1 study aimed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of veliparib combined with various FOLFIRI regimens in patients with solid tumours. METHODS: Patients received veliparib...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Cancer
Главные авторы: Berlin, Jordan, Ramanathan, Ramesh K., Strickler, John H., Subramaniam, Deepa S., Marshall, John, Kang, Yoon-Koo, Hetman, Robert, Dudley, Matthew W., Zeng, Jiewei, Nickner, Caroline, Xiong, Hao, Komarnitsky, Philip, Shepherd, Stacie Peacock, Hurwitz, Herbert, Lenz, Heinz-Josef
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933261/
https://ncbi.nlm.nih.gov/pubmed/29527010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0003-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы